Tudor Investment Corp
URGN icon

Tudor Investment Corp’s UroGen Pharma URGN Stock Holding History

Tudor Investment Corp’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,503
Closed -$226K – 3919
2025
Q2 		$226K Buy
+16,503
New +$158K ﹤0.01% 3032
2021
Q3 		– Sell
-25,048
Closed -$382K – 2816
2021
Q2 		$382K Buy
+25,048
New +$453K 0.01% 1279
2019
Q2 		– Sell
-6,235
Closed -$230K – 1350
2019
Q1 		$230K Buy
+6,235
New +$261K 0.01% 953

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Tudor Investment Corp's URGN Position: Q3 2025 in Review

Tudor Investment Corp sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 16,503 shares — an estimated $226K sold.

Tudor Investment Corp first reported a position in URGN in Q1 2019 and held it in 3 quarters. The position peaked at $382K in Q2 2021. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.

  • Tudor Investment Corp reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
  • Tudor Investment Corp sold 16,503 UroGen Pharma shares in Q3 2025, an estimated $226K.
  • Tudor Investment Corp first reported a position in UroGen Pharma in Q1 2019 and held it in 3 quarters.
  • Tudor Investment Corp's UroGen Pharma position peaked at $382K in Q2 2021.
  • 161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.

Based on Tudor Investment Corp's 13F filing for Q3 2025, filed 14 Nov 2025.